Autophagy is a conserved eukaryotic pathway which mediates the degradation of cellular components within specialized subcellular compartments, termed autophagosomes (SI- Figure 1 ). [1] Autophagy plays a crucial role in the degradation of protein aggregates involved in several neurodegenerative diseases, [2] and promotes the survival of cancer cells. [3] Novel small molecule autophagy modulators may offer new opportunities for drug discovery [4] [5] [6] and to decipher the underlying molecular mechanisms of this important cellular process. [7] Target-agnostic cellular assays monitoring changes in phenotype followed by target identification and validation offer unbiased opportunities to discover novel chemotypes and cellular targets linked to the biological process of interest by means of phenotypic changes. [8] Herein we report the discovery of a potent autophagy inhibitor by means of a phenotypic screening approach monitoring small molecule induced impairment of autophagy. [9] The compound, termed autophinib, targets the lipid kinase Vacuolar Protein Sorting 34 (VPS34) [10] which is a promising target for selective autophagy modulation. [11] To identify novel autophagy inhibitors, we employed a previously described cellular assay. [9, 13] In brief, autophagy was induced in MCF7 cells stably expressing eGFP-LC3 (enhanced green fluorescent protein tagged light chain 3; MCF7-LC3) by amino acid starvation using Earle's balanced salt solution (EBSS), or by inhibition of mTOR using Rapamycin. Accumulation of eGFP-LC3 on autophagosomes is visualized and quantified as formation of puncta by means of automated microscopy and image analysis. [13] Screening of ca. 160.000 compounds identified a class of aminopyrimidines which dose-dependently inhibited autophagosome formation (e.g. 1; Figure 1 and SI- Table 1 ). Compounds active under both starvation-and rapamycininduced autophagy were of particular interest, since they are expected to act downstream of mTOR in canonical autophagy regulation or in non-canonical autophagy independent of mTOR.
Autophagy inhibitor 1 and analogues thereof were previously developed as inhibitors of the protein kinase TBK1. [12] However, TBK1 inhibition would result in inhibition of autophagosome maturation, increased autophagosome and eGFP-LC3 puncta formation and, therefore, cannot explain the activity of the hit class in the screen. [14] (Table 1 and SI-Tables 1-5 ). This finding further supported the notion that TBK1 was not the target responsible for autophagy inhibition, as the protonated piperazine moiety generates a key salt bridge with the Asp157 in TBK1 which leads to enhanced potency toward TBK1. [12] Other smaller aminecontaining inhibitors, (e.g. Table 1 , entry 6) were also less potent in comparison to the chloro-or methyl-substituted analogues. Based on these observations a chloro-substituent at the 6-position was chosen for further compound improvement.
Replacement of the pyrazole in the 4-position led to loss of activity (Table 1, entries 9 -12) . By analogy to findings of Rauh et al., [15] this finding suggests that the pyrazole may be involved in a key hydrogen bond to the kinase hinge region. A methyl group on the pyrazole was most advantageous for activity, whilst the larger tert-butyl group (Table 1, entry 7) led to a significant drop in cellular activity.
At the 2-position (R 1 ) an ether-oxygen is favored for activity as replacement by a thioether (SI- Statistical analysis was performed using student's t-test (*** = p≤0.001). Data are shown with mean values ± 95% CI, N ≥ 25.
As expected for an autophagy inhibitor, autophinib enhanced cell death of starved cells as compared to fed cells ( Figure 2B ), [4, 6] which occurred via the induction of apoptosis ( Figure 2C ).
Since autophinib inhibited Rapamycin induced autophagy and thus acts downstream or independently of mTOR, we performed an image based flux assay quantifying the number of autophagosomes as well as autolysosomes (SI- Figure 4) . Autophinib inhibits the accumulation of autophagosomes under fed as well as starved conditions, but does not affect the number of autolysosomes. Thus it is not a late stage autophagy inhibitor but an inhibitor of autophagosome formation. PI3P is essential to initiate autophagosome biogenesis and is mainly generated by the kinase VPS34. PI3P recruits effector protein WIPI2, which is important for the formation of autophagosomes. [17] Therefore, eGFP-WIPI2b serves as a sensor for autophagosomal PI3P. [18] Image analysis of HEK293A cells, stably transfected with a construct for eGFP fused to WIPI2b, showed an increasing number of fluorescent vesicles upon starvation, which was reduced upon treatment with autophinib ( Figure 2D and E, see SI- Figure 5 for the full image set).
For target identification autophinib was profiled on a proteome-wide level by comparing it to compounds with known modes of action and targets ( Figure 3A ,
SI-Tables 6-8). The ChemProteoBase method employs image based proteome analysis by means of 2-D difference gel electrophoresis (DIGE) in comparison
to reference compounds. [19] Since no compound with similarity > 0.7 was identified in this analysis, the mechanism of action of autophinib is suggested to be novel. Despite a low cosine value, several kinase inhibitors emerged at the top of the list such as the PI3K inhibitor LY294002 (SI- Table 7 ). This finding in combination with the potent effect of autophinib on the formation of PI3P containing puncta and structural similarity to known kinase inhibitors led us to investigate inhibition of the PI3 kinase VPS34 by autophinib.
Indeed, VPS34 was inhibited with IC50 values of 19 ± 5 nM and 51 ± 8 nM at ATP concentrations of KM (10 µM) and 100 µM respectively ( Figure 3B) 11 suggesting an ATP competitive mode of action. Activity in the phenotypic assay correlated strongly with in vitro potency against VPS34 (Table 1 ). Autophinib did not inhibit other phosphatidylinositol kinases and mTOR at a concentration of 1 µM (SI- Table 9 ). Remarkably, it also did not inhibit TBK1, the target of the parent compound 1. Selectivity was further assessed in a panel of >460 kinases (SI-File 1) from which 45 were inhibited ≥ 80% at a concentration of 1 µM. However, most of them could be excluded as being not relevant for autophagy by testing known, selective inhibitors in the autophagy assay (SI Table 10 ). Among 27 investigated inhibitors, the most potent autophagy inhibitory activity was observed for the two recently reported VPS34 inhibitors:
SAR405 and VPS34-IN-1. [20, 21] VPS34 engagement by autophinib in a complex biological medium was demonstrated by means of an ActiveX assay [22] , [23] , which employs a reactive Figure 3C ). This result further supports the notion that autophinib is an ATP competitive VPS34 inhibitor.
An isothermal dose-response fingerprint (ITDRF) [24] confirmed target engagement of autophinib in cell lysate, which stabilized VPS34 towards heat induced aggregation (SI- Figure 6 ).
In summary, we report the discovery of a new autophagy inhibitor chemotype by means of phenotypic screening. Autophinib targets VPS34 but not other lipid kinases, mTOR and TBK1. Autophinib appears to be ATP-competitive, targets VPS34 in cell lysate and induces cellular phenotypes consistent with VPS34
inhibition.
Wortmannin and 3-methyladenine (3-MA) have been used widely to study the effect of PIK3 inhibition. However, both non-selectively inhibit all isoforms of the PIK3 family. [25] In addition it has been observed that conditional knockout of VPS34 shows severe differences to 3-MA or wortmannin treatment, indicating that these inhibitors display VPS34-independent effects. [26] Recently more potent and selective alternatives have been developed. [20, 21] However, an expanded toolkit to study autophagy and VPS34 activity would be very desirable for basic research and potential drug discovery applications.
Autophinib distinguishes itself by its ready synthetic accessibility (3 steps, overall yield: 45%), combined with high in vitro potency, selectivity and cellular activity. It promises to be an excellent tool compound for the study of VPS34 biology and autophagy. Our results provide further proof for the utility of 
